{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:13:24Z","timestamp":1779203604575,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-34984-x","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:21:12Z","timestamp":1767630072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen"],"prefix":"10.1038","volume":"16","author":[{"given":"Wataru","family":"Kikushima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Kotoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne Viel","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"34984_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","volume":"117","author":"R Kawasaki","year":"2010","unstructured":"Kawasaki, R. et al. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology 117, 921\u2013927. https:\/\/doi.org\/10.1016\/j.ophtha.2009.10.007 (2010).","journal-title":"Ophthalmology"},{"key":"34984_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"W. L. Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health 2, e106\u2013116 (2014).","journal-title":"Lancet Glob Health"},{"key":"34984_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481 (2006).","journal-title":"N Engl. J. Med."},{"key":"34984_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006 (2012).","journal-title":"Ophthalmology"},{"key":"34984_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.oret.2021.08.009","volume":"6","author":"E Moisseiev","year":"2022","unstructured":"Moisseiev, E., Tsai, Y. L. & Herzenstein, M. Treatment of neovascular age-related macular degeneration: An economic cost-risk analysis of anti-vascular endothelial growth factor agents. Ophthalmol. Retina 6, 205\u2013212. https:\/\/doi.org\/10.1016\/j.oret.2021.08.009 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"34984_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","volume":"21","author":"L Ferro Desideri","year":"2021","unstructured":"Ferro Desideri, L., Traverso, C. E. & Nicolo, M. Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD. Expert Opin. Biol. Ther. 21, 553\u2013561. https:\/\/doi.org\/10.1080\/14712598.2021.1915278 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"34984_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","volume":"244","author":"R Tadayoni","year":"2021","unstructured":"Tadayoni, R. et al. Brolucizumab: A newly developed Anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica 244, 93\u2013101. https:\/\/doi.org\/10.1159\/000513048 (2021).","journal-title":"Ophthalmologica"},{"key":"34984_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen, Q. D. et al. Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127, 963\u2013976. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031 (2020).","journal-title":"Ophthalmology"},{"key":"34984_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017 (2020).","journal-title":"Ophthalmology"},{"key":"34984_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128, 89\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.028 (2021).","journal-title":"Ophthalmology"},{"key":"34984_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s, J. et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology 128, 1050\u20131059. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011 (2021).","journal-title":"Ophthalmology"},{"key":"34984_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","volume":"140","author":"AM Khanani","year":"2022","unstructured":"Khanani, A. M. et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: Results from the IRIS registry and Komodo healthcare map. JAMA Ophthalmol. 140, 20\u201328. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.4585 (2022).","journal-title":"JAMA Ophthalmol."},{"key":"34984_CR13","doi-asserted-by":"publisher","first-page":"e27580","DOI":"10.1097\/MD.0000000000027580","volume":"100","author":"Y Shigemoto","year":"2021","unstructured":"Shigemoto, Y. et al. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation. Medicine 100, e27580. https:\/\/doi.org\/10.1097\/MD.0000000000027580 (2021).","journal-title":"Med. (Baltim)."},{"key":"34984_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","volume":"139","author":"AB Enriquez","year":"2021","unstructured":"Enriquez, A. B. et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 139, 441\u2013448. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.7085 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"34984_CR15","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/jcm10132758","volume":"10","author":"A. Bilgic","year":"2021","unstructured":"Bilgic, A. et al. Real-world experience with brolucizumab in wet age-related macular degeneration: The REBA study. J. Clin. Med. 10, 2758. https:\/\/doi.org\/10.3390\/jcm10132758 (2021).","journal-title":"J. Clin. Med."},{"key":"34984_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15242","author":"CR Baumal","year":"2022","unstructured":"Baumal, C. R. et al. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.15242 (2022).","journal-title":"Acta Ophthalmol."},{"key":"34984_CR17","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/biomedicines9091164","volume":"9","author":"Y Fukuda","year":"2021","unstructured":"Fukuda, Y. et al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines 9, 1164 (2021).","journal-title":"Biomedicines"},{"key":"34984_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ph16040562","volume":"16","author":"W. Kikushima","year":"2023","unstructured":"Kikushima, W. et al. A treat-and-extend regimen of intravitreal brolucizumab for exudative age-related macular degeneration refractory to aflibercept: A 12-month result. Pharmaceuticals 16, 562. https:\/\/doi.org\/10.3390\/ph16040562 (2023).","journal-title":"Pharmaceuticals"},{"key":"34984_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10384-023-00999-4","volume":"67","author":"Y Fukuda","year":"2023","unstructured":"Fukuda, Y. et al. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy. Jpn J. Ophthalmol. 67, 402\u2013409. https:\/\/doi.org\/10.1007\/s10384-023-00999-4 (2023).","journal-title":"Jpn J. Ophthalmol."},{"key":"34984_CR20","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s12325-022-02193-3","volume":"39","author":"RP Finger","year":"2022","unstructured":"Finger, R. P. et al. Comparative efficacy of Brolucizumab in the treatment of neovascular age-related macular degeneration: A systematic literature review and network meta-analysis. Adv. Ther. 39, 3425\u20133448. https:\/\/doi.org\/10.1007\/s12325-022-02193-3 (2022).","journal-title":"Adv. Ther."},{"key":"34984_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000529817","volume":"246","author":"A Scupola","year":"2023","unstructured":"Scupola, A. et al. Brolucizumab for wet age-related macular degeneration: One-year real-world experience from a tertiary center. Ophthalmologica 246, 58\u201367. https:\/\/doi.org\/10.1159\/000529817 (2023).","journal-title":"Ophthalmologica"},{"key":"34984_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ophtha.2023.04.012","volume":"130","author":"MW MacCumber","year":"2023","unstructured":"MacCumber, M. W. et al. One-year brolucizumab outcomes in neovascular age-related macular degeneration from a large united States cohort in the IRIS\u00ae registry. Ophthalmology 130, 937\u2013946. https:\/\/doi.org\/10.1016\/j.ophtha.2023.04.012 (2023).","journal-title":"Ophthalmology"},{"key":"34984_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","volume":"MERLIN","author":"AM Khanani","year":"2022","unstructured":"Khanani, A. M. et al. MERLIN: Phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology 129, 974\u2013985. https:\/\/doi.org\/10.1016\/j.ophtha.2022.04.028 (2022).","journal-title":"Ophthalmol. 129"},{"key":"34984_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/IAE.0000000000003994","volume":"44","author":"W Kikushima","year":"2024","unstructured":"Kikushima, W. et al. Incidence and characteristics of neovascular age-related macular with over a 12-month remission after three monthly aflibercept administration: 60 months results of a pro re nata regimen. Retina 44, 498\u2013505. https:\/\/doi.org\/10.1097\/IAE.0000000000003994 (2024).","journal-title":"Retina"},{"key":"34984_CR25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/iae.0000000000003556","volume":"42","author":"FG Holz","year":"2022","unstructured":"Holz, F. G. et al. Patient selection, evaluation, and treatment. Retina 42, 1629\u20131637. https:\/\/doi.org\/10.1097\/iae.0000000000003556 (2022).","journal-title":"Retina"},{"key":"34984_CR26","doi-asserted-by":"publisher","first-page":"e0259879","DOI":"10.1371\/journal.pone.0259879","volume":"16","author":"R Mukai","year":"2021","unstructured":"Mukai, R., Matsumoto, H. & Akiyama, H. Risk factors for emerging intraocular inflammation after intravitreal Brolucizumab injection for age-related macular degeneration. PLoS One. 16, e0259879. https:\/\/doi.org\/10.1371\/journal.pone.0259879 (2021).","journal-title":"PLoS One"},{"key":"34984_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/IAE.0000000000004009","volume":"44","author":"S Inoda","year":"2024","unstructured":"Inoda, S. et al. Incidence and risk factors of intraocular inflammation after Brolucizumab treatment in Japan: A multicenter age-related macular degeneration study. Retina 44, 714\u2013722. https:\/\/doi.org\/10.1097\/IAE.0000000000004009 (2024).","journal-title":"Retina"},{"key":"34984_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris III","year":"2013","unstructured":"Ferris III, F. L. et al. Clinical classification of age-related macular degeneration. Ophthalmology 120, 844\u2013851. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.036 (2013).","journal-title":"Ophthalmology"},{"key":"34984_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi, L. A., Sorenson, J., Spaide, R. F. & Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10, 1\u20138 (1990).","journal-title":"Retina"},{"key":"34984_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung, C. M. G. et al. Polypoidal choroidal vasculopathy: Consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology 128, 443\u2013452. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.006 (2021).","journal-title":"Ophthalmology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-34984-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-34984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-34984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:00:38Z","timestamp":1770195638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-34984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-34984-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4739"}}